Jennifer L. McNeer

Jennifer L. McNeer, MD, MSCI

Languages spoken: English

Clinical Locations

Primary Children's Hospital

Pediatric Hematology/Oncology
801-662-4830

University of Utah Hospital

University Pediatric Clinic
801-581-2205

  • Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children’s Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children’s Hospital.

    After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children’s Memorial Hospital (now Lurie Children’s Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children’s Memorial Hospital, and during her fellowship earned a master’s degree in clinical investigation at Northwestern University Feinberg School of Medicine.

    Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children’s Oncology Group.

    Dr. McNeer’s clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children’s Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.

    Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children’s Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children’s Hospital.

    After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children’s Memorial Hospital (now Lurie Children’s Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children’s Memorial Hospital, and during her fellowship earned a master’s degree in clinical investigation at Northwestern University Feinberg School of Medicine.

    Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children’s Oncology Group.

    Dr. McNeer’s clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children’s Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.

    Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Graduate Training Clinical Investigation - Northwestern University Feinberg School of Medicine M.S.C.I
    Pediatric Hematology/Oncology/Stem Cell Transplant - Northwestern University Feinberg School of Medicine Fellow
    Residency Pediatrics - Northwestern University Feinberg School of Medicine Resident
    Medicine - New York University College of Medicine M.D.
    Undergraduate Biology - University of Virginia B.A. (Hons)

    Selected Publications

    Journal Article

    1. Elgarten CW, Thompson JC, Angiolillo A, Chen Z, Conway S, Devidas M, Gupta S, Kairalla JA, McNeer JL, OBrien MM, Rabin KR, Rau RE, Rheingold SR, Wang C, Wood C, Raetz EA, Loh ML, Alexander S, Miller TP (2022). Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer, 69(11), e29937.
    2. Kaumeyer B, Fidai S, Sukhanova M, Yap KL, Segal J, Raca G, Stock W, McNeer J, Lager AM, Gurbuxani S (2022). MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma, 63(6), 1436-1444.
    3. Schulte R, Hinson A, Huynh V, Breese EH, Pierro J, Rotz S, Mixon BA, McNeer JL, Burke MJ, Orgel E (2021). Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med, 10(21), 7551-7560.
    4. Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K (2021). Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov, 11(6), 1424-1439.
    5. Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W (2020). Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv, 5(2), 504-512.
    6. Gupta S, Maude SL, OBrien MM, Rau RE, McNeer JL (2020). How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. Clin Lymphoma Myeloma Leuk, 20 Suppl 1, S8-S11.
    7. Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, McNeer JL, Stock W, Stovall M, Krull KR, Sklar CA, Neglia JP, Armstrong GT, Oeffinger KC, Robison LL, Henderson TO (2020). Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol, 21(3), 421-435.
    8. Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH (2019). Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. J Clin Oncol, 37(23), 2072-2081.
    9. Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, OBrien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR (2018). Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia, 33(4), 884-892.
    10. McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA (2019). Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. J Clin Oncol, 37(10), 780-789.
    11. Henderson JR 2nd, Kiernan E, McNeer JL, Rodday AM, Spencer K, Henderson TO, Parsons SK (2017). Patient-Reported Health-Related Quality-of-Life Assessment at the Point-of-Care with Adolescents and Young Adults with Cancer. J Adolesc Young Adult Oncol, 7(1), 97-102.
    12. Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM (2017). Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer, 124(1), 136-144.
    13. Yap KL, Furtado LV, Kiyotani K, Curran E, Stock W, McNeer JL, Kadri S, Segal JP, Nakamura Y, Le Beau MM, Gurbuxani S, Raca G (2016). Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma, 58(4), 950-958.
    14. Muffly L, Lichtensztajn D, Shiraz P, Abraho R, McNeer J, Stock W, Keegan T, Gomez SL (2016). Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer, 123(1), 122-130.
    15. Villanueva G, de Jong JL, McNeer JL (2017). Intravenous Immunoglobulin in the Treatment of Hematologic Disorders in Pediatrics. Pediatr Ann, 46(1), e13-e18.
    16. Petty LA, Sokol EA, Bartlett AH, McNeer JL, Alexander KA, Pisano J (2016). Repeated Blood Cultures in Pediatric Febrile Neutropenia: Would Following the Guidelines Alter the Outcome? Pediatr Blood Cancer, 63(7), 1244-9.
    17. Muffly LS, Hlubocky FJ, Khan N, Wroblewski K, Breitenbach K, Gomez J, McNeer JL, Stock W, Daugherty CK (2016). Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer, 122(6), 954-61.
    18. Alperstein W, Boren M, McNeer JL (2015). Pediatric Acute Lymphoblastic Leukemia: From Diagnosis to Prognosis. Pediatr Ann, 44(7), e168-74.
    19. McNeer JL (2014). The identity crisis of Krüppel-like factor 4. Leuk Lymphoma, 55(8), 1703-4.
    20. McNeer JL (2011). The complex interplay between folate metabolism and risk of acute lymphoblastic leukemia. Leuk Lymphoma, 52(9), 1621-2.
    21. Goussetis DJ, Altman JK, Glaser H, McNeer JL, Tallman MS, Platanias LC (2010). Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem, 285(39), 29989-97.
    22. McNeer JL, Goussetis DJ, Sassano A, Dolniak B, Kroczynska B, Glaser H, Altman JK, Platanias LC (2010). Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Mol Pharmacol, 77(5), 828-35.
    23. McNeer JL, Kletzel M, Rademaker A, Alford K, ODay K, Schaefer C, Duerst R, Jacobsohn DA (2009). Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 16(3), 350-7.
    24. Craig ML, Bankovich AJ, McElhenny JL, Taylor RP (2000). Clearance of anti-double-stranded DNA antibodies: the natural immune complex clearance mechanism. Arthritis Rheum, 43(10), 2265-75.

    Review

    1. McNeer JL, Schmiegelow K (2022). Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia. [Review]. Curr Hematol Malig Rep, 17(1), 1-14.
    2. McNeer JL, Rau RE, Gupta S, Maude SL, OBrien MM (2020). Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. [Review]. Am Soc Clin Oncol Educ Book, 40, 1-12.
    3. Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, DuVall A, Bleyer A (2018). Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. [Review]. Leuk Lymphoma, 59(10), 2360-2368.
    4. McNeer JL, Bleyer A (2018). Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. [Review]. Pediatr Blood Cancer, 65(6), e26989.
    5. McNeer JL, Raetz EA (2012). Acute lymphoblastic leukemia in young adults: which treatment? [Review]. Curr Opin Oncol, 24(5), 487-94.
    6. McGregor S, McNeer J, Gurbuxani S (2012). Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. [Review]. Semin Diagn Pathol, 29(1), 2-11.
    7. McNeer JL, Nachman JB (2010). The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. [Review]. Br J Haematol, 149(5), 638-52.

    Editorial

    1. McNeer JL (2015). Pediatric Hematology, Oncology, and Stem Cell Transplantation. Pediatr Ann, 44(7), 278-9.

    Letter

    1. Raca G, Gurbuxani S, Zhang Z, Li Z, Sukhanova M, McNeer J, Stock W (2014). RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. [Letter to the editor]. Leuk Lymphoma, 56(4), 1145-7.
    2. Morales La Madrid A, Ouyang K, Raca G, Jamali M, Hyjek E, McNeer JL, Anastasi J (2012). A case of pediatric γ/δ T-cell malignancy with t(8;14)(q24;q11)/MYC-TCR successfully treated with pulse type chemotherapy followed by stem cell transplant. [Letter to the editor]. Leuk Lymphoma, 54(2), 403-5.

  • News & Podcasts